Inovio Releases Preliminary Phase 1 COVID-19 Results

Inovio has released preliminary results of a phase 1 clinical trial of its DNA-based COVID-19 vaccine INO-4800.

Of the 36 patients who received the vaccine, 94 percent demonstrated an immune response six weeks after either two 1mg or 2mg doses. No serious adverse events were reported.  

The company expects to initiate a phase 2/3 trial this summer.